Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target
Madhusoodanan Mottamal, Bo-Rui Kang, Xianyou Peng, et al.
ACS Omega (2021) Vol. 6, Iss. 14, pp. 9334-9343
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 148
Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
Nicholas P. McAndrew, Richard S. Finn
JCO Oncology Practice (2021) Vol. 18, Iss. 5, pp. 319-327
Open Access | Times Cited: 76
Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
Teesha Downton, Fiona H. Zhou, Davendra Segara, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 2933-2948
Open Access | Times Cited: 45
Vanillin-Based Indolin-2-one Derivative Bearing a Pyridyl Moiety as a Promising Anti-Breast Cancer Agent via Anti-Estrogenic Activity
Onur Bender, İsmail Çeli̇k, Rumeysa Dogan, et al.
ACS Omega (2023) Vol. 8, Iss. 7, pp. 6968-6981
Open Access | Times Cited: 26
Novel Estrogen Receptor-Targeted Agents for Breast Cancer
Mythili Shastry, Erika Hamilton
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 7, pp. 821-844
Closed Access | Times Cited: 16
Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives
Si Ha, Jiacheng Zhu, Hua Xiang, et al.
Chinese Chemical Letters (2023) Vol. 35, Iss. 8, pp. 109192-109192
Closed Access | Times Cited: 16
Estrogen Receptor Alpha Binders for Hormone-Dependent Forms of Breast Cancer: e-QSAR and Molecular Docking Supported by X-ray Resolved Structures
Vijay H. Masand, Sami A. Al‐Hussain, Abdullah Yahya Abdullah Alzahrani, et al.
ACS Omega (2024) Vol. 9, Iss. 14, pp. 16759-16774
Open Access | Times Cited: 7
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclibversusletrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
Aditya Bardia, Javier Cortés, Sara A. Hurvitz, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 24
PROTAC: Novel degradable approach for different targets to treat breast cancer
Zhenjie Wang, Siyao Che, Zhiqiang Yu
European Journal of Pharmaceutical Sciences (2024) Vol. 198, pp. 106793-106793
Open Access | Times Cited: 5
Estradiol (E2) concentration shapes the chromatin binding landscape of estrogen receptor alpha
Amy Han, Kiran Paul, Satyanarayan Rao, et al.
Journal of Biological Chemistry (2025), pp. 108499-108499
Open Access
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer
Jackson Liang, Xiaosai Yao, Patrick Aouad, et al.
Nature Cancer (2025)
Closed Access
An Estrogen Receptor β Agonist with AR Antagonist Activity from a Modern Asymmetric De Novo Steroid Synthesis
Andrea R. Bucknam, Joshua M. Nicholson, Hanna S. Radomska, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 4, pp. 631-637
Closed Access
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
Jackson Liang, Ellen Ingalla, Xiaosai Yao, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 663
Closed Access | Times Cited: 13
Current Status and Future Perspectives of Antibody–Drug Conjugates in Hormone Receptor-Positive Breast Cancer
Maria Grammoustianou, Foteinos‐Ioannis Dimitrakopoulos, Angelos Koutras
Cancers (2024) Vol. 16, Iss. 10, pp. 1801-1801
Open Access | Times Cited: 2
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
Fernanda Cardoso da Silva, Douglas Cardoso Brandão, Everton Allan Ferreira, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1466-1466
Open Access | Times Cited: 5
Urolithin A: A promising selective estrogen receptor modulator and 27‐hydroxycholesterol attenuator in breast cancer
Ravindran Vini, Vishnu Sunil Jaikumar, Viji Remadevi, et al.
Phytotherapy Research (2023) Vol. 37, Iss. 10, pp. 4504-4521
Closed Access | Times Cited: 4
Cyclopia extracts act as selective estrogen receptor subtype downregulators in estrogen receptor positive breast cancer cell lines: Comparison to standard of care breast cancer endocrine therapies and a selective estrogen receptor agonist and antagonist
Folasade R. Olayoku, Nicolette J. D. Verhoog, Ann Louw
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Interactions governing transcriptional activity of nuclear receptors
Sabab Hasan Khan, C. Denise Okafor
Biochemical Society Transactions (2022) Vol. 50, Iss. 6, pp. 1941-1952
Closed Access | Times Cited: 4
Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies
Jiawang Liu, Nirmal Rajasekaran, Ahamed Hossain, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 8, pp. 719-719
Open Access | Times Cited: 5
Endokrinpharmakologie
Thomas Gudermann, Ursula Storch, Ingrid Boekhoff
Springer eBooks (2024), pp. 617-667
Closed Access
Estradiol (E2) concentration shapes the chromatin binding landscape of the estrogen receptor
Amy Han, Kiran Paul, Satyanarayan Rao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Immunohistochemical Profiling of HER-2/neu, Steroid Hormone Receptors and KI-67 Biomarkers in a Cohort of Nigerian Women with Breast Cancer
OmobolajiO Ayandipo, GabrielO Ogun, OlalekanJ Adepoju, et al.
Journal of West African College of Surgeons (2023) Vol. 13, Iss. 2, pp. 7-15
Open Access
Structural determinants of pure antiestrogenicity
Marine Diennet, Faraz Shaikh, Mohamed El Ezzy, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Computational approaches to identify a novel binding site of BHPI on estrogen receptor alpha
Monica Bean, Reham A Alkohaif, Ahed Anbari, et al.
Steroids (2022) Vol. 186, pp. 109075-109075
Open Access
Stability of Steroid Hormone Receptors
Zachary J. Gale‐Day, Jason E. Gestwicki
(2022), pp. 27-64
Closed Access
Page 1 - Next Page

Scroll to top